NLRP3 (D4D8T) Rabbit mAb

抗體名： NLRP3（D4D8T）兔單克隆抗體 濃度： 見優(yōu)寧維 % 靶點(diǎn)： 見優(yōu)寧維 宿主： Rabbit 用途范圍： 詳見說(shuō)明書 ......

溫馨提示:優(yōu)寧維所有產(chǎn)品和服務(wù)僅用于科學(xué)研究,不用于臨床等診斷及其他用途提供產(chǎn)品和服務(wù)(也不為任何個(gè)人提供產(chǎn)品和服務(wù))! 

反應(yīng)性	H M
靈敏度	內(nèi)源性
MW (kDa)	110
來(lái)源/同種型	兔 IgG

應(yīng)用關(guān)鍵詞:

• WB- 蛋白質(zhì)印跡法
• IP-免疫沉淀法
• IHC-免疫組織化學(xué)法
• ChIP-染色質(zhì)免疫沉淀法
• IF-免疫熒光法
• F-流式細(xì)胞術(shù)
• E-P-ELISA 肽

物種交叉反應(yīng)性關(guān)鍵詞:

• H-人
• M-小鼠
• R-大鼠
• Hm- 倉(cāng)鼠
• Mk-猴
• Vir- 病毒
• Mi-水貂
• C-雞
• Dm-黑腹果蠅
• X-爪蟾
• Z-斑馬魚
• B-牛
• DG-犬
• PG-豬
• Sc-釀酒酵母
• Ce-秀麗隱桿線蟲
• Hr-馬
• All-預(yù)期所有物種

background

The nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) protein family is a diverse family of cytoplasmic innate immune receptors. They are characterized by the presence of an amino-terminal effector domain, usually a caspase activation and recruitment domain (CARD) or a pyrin domain (PYD), followed by a NACHT domain and a carboxyl group involved in the recognition of pathogen-associated molecular patterns (PAMPs) Terminal leucine-rich repeats (LRRs) (1). NLR proteins play various roles in the innate immune response, including detection of pathogens, transcriptional activation of proinflammatory cytokines through NF-κB, transcriptional activation of type I interferons through IRF, and formation of inflammasomes that activate inflammatory caspases (1-7 ).
NLRP3 is an inflammasome-forming NLR that activates caspase-1 to mature IL-1β and IL-18 (8). The NLRP3 inflammasome does not assemble until after a variety of microbial and endogenous stimuli, so it is unlikely that NLRP3 interacts directly with its activators (8). NLRP3 expression reaches highest levels in dendritic cells, monocytes and macrophages (9).

1. Elinav, E. et al. (2011) Immunity 34, 665-79.
2. Inohara, N. et al. (1999) J Biol Chem 274, 14560-7.
3. Ogura, Y. et al. (2001) J Biol Chem 276, 4812-8.
4. Sabbah, A. et al. (2009) Nat Immunol 10, 1073-80.
5. Mariathasan, S. et al. (2004) Nature 430, 213-8.
6. Agostini, L. et al. (2004) Immunity 20, 319-25.
7. Martinon, F. et al. (2002) Mol Cell 10, 417-26.
8. Franchi, L. et al. (2012) Nat Immunol 13, 325-32.
9. Guarda, G. et al. (2011) J Immunol 186, 2529-34.